A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

This study is collecting real-world information on patients with a blood cancer called mantle cell lymphoma (MCL) who received a CAR-T cell therapy called lisocabtagene maraleucel (liso-cel) in a commercial (non-trial) setting. CAR-T therapy reprograms the patient's own immune cells to hunt down cancer. The study documents how well this treatment works in everyday clinical practice. **You may be eligible if...** - You have relapsed or refractory mantle cell lymphoma (cancer that came back or did not respond to prior treatment) - You received at least one infusion of liso-cel as a commercially approved treatment in the United States - Your treatment followed the FDA-approved dose and guidelines **You may NOT be eligible if...** - You were participating in another investigational study at the time you received liso-cel - The CAR-T cell product you received did not meet commercial quality specifications Talk to your doctor to see if this trial is right for you.